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Abstract 24 Arthropod-borne viruses represent a significant public health threat worldwide yet there are few 25 antiviral therapies or prophylaxis targeting these pathogens. In particular, the development of 26 novel antivirals for high-risk populations such as pregnant women is essential to prevent 27 devastating disease such as that which was experienced with the recent outbreak of Zika virus 28 (ZIKV) in the Americas. One potential avenue to identify new and pregnancy friendly antiviral 29 compounds is to repurpose well-known and widely used FDA approved drugs. In this study, we 30 addressed the antiviral role of atovaquone, a FDA Pregnancy Category C drug and pyrimidine 31 biosynthesis inhibitor used for the prevention and treatment of parasitic infections. We found that 32 atovaquone was able to inhibit ZIKV and chikungunya virus virion production in human cells and 33 that this antiviral effect occurred early during infection at the initial steps of viral RNA replication.
34
Moreover, we were able to complement viral replication and virion production with the addition of 35 exogenous pyrimidine nucleosides indicating that atovaquone is functioning through the inhibition 36 of the pyrimidine biosynthesis pathway to inhibit viral replication. Finally, using an ex vivo human 37 placental tissue model, we found that atovaquone could limit ZIKV infection in a dose-dependent 38 manner providing evidence that atovaquone may function as an antiviral in humans. Taken 39 together, these studies suggest that atovaquone could be a broad-spectrum antiviral drug and a 40 potential attractive candidate for the prophylaxis or treatment of arbovirus infection in vulnerable 41 populations, such as pregnant women. The ability to protect vulnerable populations such as pregnant women and children from Zika virus 49 and other arbovirus infections is essential to preventing the devastating complications induced by 50 these viruses. One class of antiviral therapies may lie in known pregnancy-friendly drugs that 51 have the potential to mitigate arbovirus infections and disease yet this has not been explored in 52 detail. In this study, we show that the common antiparasitic drug, atovaquone, inhibits arbovirus 53 replication through intracellular nucleotide depletion and can impair ZIKV infection in an ex vivo 54 human placental explant model. Our study provides a novel function for atovaquone and 55 highlights that the rediscovery of pregnancy-acceptable drugs with potential antiviral effects can 56 be the key to better addressing the immediate need for treating viral infections and preventing 57 potential birth complications and future disease.
87
to repurpose existing drugs with an acceptable profile in pregnancy.
88
Nucleotide biosynthesis inhibitors such as ribavirin, brequinar, and mycophenolic acid (MPA) 89 have been shown extensively to inhibit a wide array of viral infections both in vitro and in vivo [17] ,
90
[18], [19] , [20] , [21] [22], [23] . In addition, a number of small compounds that possess antiviral 91 function through the depletion of intracellular nucleotide pools have been identified, suggesting 92 that this cellular pathway may be a prime target for antiviral development [24] , [25] , [26] , [27] , [28] .
93
Unfortunately, many of these compounds have numerous side effects and are not approved for brequinar, known nucleotide biosynthesis inhibitors shown to have antiviral function (Figure 1) .
129
The cells were subsequently infected with either the Ugandan or Brazilian strains of Zika virus 130 (ZIKV) and viral inhibition was assessed 72 hours post infection by immunostaining for the ZIKV 131 envelope (E) protein. We found that all known nucleotide biosynthesis inhibitors were able to 132 inhibit ZIKV replication although in a strain specific manner (Figure 1A-C) . Importantly, we found 133 that atovaquone exhibited similar antiviral activity over the concentrations tested and that this 134 inhibition was again strain specific ( Figure 1D-F) . Taken together, these studies show that 135 atovaquone inhibits ZIKV infection and spread, potentially through the depletion of intracellular 136 nucleotide pools.
137
Atovaquone impairs ZIKV virion production in human cells. Given the inhibition of viral 138 replication in Vero cells, we next addressed whether atovaquone was able to reduce the 139 production of infectious ZIKV particles in mammalian cell types including human cells. For these 140 and all subsequent studies, we chose to use the Ugandan strain of ZIKV due to its robust 141 replication in vitro and its relative resistance to atovaquone compared to the Brazilian strain 142 (Figure 1) . We infected Vero, human 293T and human placental JEG3 cells with the Ugandan 7 143 strain of ZIKV in the presence of atovaquone or a DMSO control and quantified infectious virion 144 production by plaque assay. We found that atovaquone significantly impaired virion production in 145 all cell types tested although the peak of inhibition varied between cell type (Figure 2A-C) .
146
One potential explanation for these results could be that atovaquone is toxic, and this 147 leads to reduced virus production. To address this, we first measured cell viability by a MTT cell 148 proliferation assay and found that atovaquone indeed had a dose-dependent reduction in cell 149 proliferation compared to the DMSO control ( Figure S1A ). However, atovaquone is a 150 mitochondrial cytochrome complex III inhibitor [33, 36, 44] and thus we hypothesized that the MTT 151 assay results we observed may be due to mitochondrial inhibition and are not directly indicative 152 of dying cells. To confirm this, we measured cell viability with Sytox Green, a dye that binds nucleic 153 acids when both the plasma and the nuclear membrane are permeabilized and thus represents 154 dying cells ( Figure S1B ). Using this assay, we found that high concentrations of atovaquone, 155 particularly in 293T cells, did lead to more cell death than the DMSO control; however, lower 156 concentration, that did show effects by the MTT assay, had minimal effects on cell viability.
157
Moreover, these results were confirmed in our data as although we observed a reduction in cell 158 growth by MTT assay we found that in Vero and 293T cells, virus production increased at higher 159 concentrations of atovaquone suggesting that the cells are still competent for virus production 160 under these conditions. Taken together, these results show that atovaquone is able to inhibit ZIKV 161 virion production in mammalian and human cell types.
162
To expand on these findings, we addressed if atovaquone could inhibit chikungunya virus Figure 3A) . This inhibition in replication was further 170 confirmed in Vero and 293T cells where we observed reductions in infectious CHIKV virions after 171 treatment with atovaquone ( Figure 3B) . These results suggest that atovaquone can inhibit 172 multiple arboviruses and has the potential to be used as a well-tolerated antiviral therapy. hypothesized that atovaquone may function through a similar pathway. To address this, we 196 performed a rescue experiment where we infected cells with ZIKV in the presence of atovaquone 197 or DMSO followed by media with atovaquone supplemented with 100 M uridine, cytidine, 198 adenosine, or guanosine. We found that in all cells types, ZIKV infectious particle production was 199 rescued only when uridine was added to the media (Figure 5A-C) . Given these results and the 200 dual function of atovaquone in blocking both mitochondrial function and DHODH, it is possible 201 that the addition of exogenous nucleosides could simply have rescued the MTT phenotype 202 (mitochondrial function) we see for atovaquone and thus ZIKV replication. However, we found 203 that when cells were incubated in the presence of atovaquone and nucleoside there was no 204 change in MTT cell proliferation (Figure S2) , indicating that the ZIKV inhibition and rescue we 205 observe is not through mitochondrial inhibition but rather through the inhibition of DHODH.
206
Furthermore, we addressed the ability of uridine to complement ZIKV RNA synthesis and found 207 that indeed the addition of exogenous uridine rescued this phenotype to similar levels of the 208 DMSO control (Figure 5D ). Taken together, these results suggest that atovaquone is functioning 209 through the depletion of intracellular nucleotide pools, and the addition of exogenous uridine can 210 rescue ZIKV replication via the pyrimidine salvage pathway, bypassing the inhibition of 211 atovaquone at critical steps in the de novo pyrimidine synthesis inhibition. 10 217
Similar to data in cell lines, we found that ZIKV infection and virion production were inhibited in a 218 dose-dependent manner in the human placental tissue (Figure 6A) . These results were confirmed 219 by fluorescence in situ hybridization probing for ZIKV RNA in ZIKV infected tissue where 220 atovaquone treatment reduced ZIKV spread (Figure 6B) 
248
MPA, and brequinar, for their ability to inhibit two genetically distant strains of ZIKV. We found 249 that ribavirin, MPA, and brequinar were able to inhibit ZIKV replication as has been shown 250 previously and that atovaquone also led to inhibition of ZIKV replication behaving similarly to the 251 pyrimidine biosynthesis inhibitor brequinar. Interestingly, we found that there was a strain-specific 252 impact of the nucleotide biosynthesis inhibitors suggesting that genetic differences between the
253
Ugandan and Brazilian strains may be responsible for the sensitivity to nucleotide depletion.
254
Nonetheless, we concluded that atovaquone inhibits ZIKV replication similarly to other nucleotide 255 biosynthesis inhibitors in Vero cells.
256
One potential caveat of these experiments could be that whereas we do detect reductions 257 in ZIKV infected cells by immunofluorescence, this could have little impact on infectious virion 258 production. To address this, we quantified infectious virus in the supernatant in the presence of 259 atovaquone treatment compared to a DMSO control. As we saw with immunofluorescence,
260
atovaquone was able to significantly reduce the amount of infectious virus in multiple mammalian 261 cell types, including human placental cells over a subset of drug concentrations. Interestingly we 262 found that in Vero and 293T cells, higher concentrations of drug had the least impact on virion 263 production. One explanation for this could be that the virus has evolved to be resistant to 264 atovaquone. However, we find this unlikely given the short time of infection and that drug 265 resistance typically takes multiple passages. An additional explanation could be that at high 266 concentrations, atovaquone is interfering with other cellular pathways that impede its antiviral 12 267 effects yet still results in the inhibition of mitochondrial function in vitro. This may be of particular 268 importance for the use of atovaquone as an antiviral in humans. In the in vitro human cell culture 269 system, the CC 50 of atovaquone was roughly 10 M which contrasts with historical trials of 270 atovaquone taken orally at a doses of 750 mg every 6 hours for the treatment of toxoplasmosis,
271
reporting steady serum concentrations in humans of roughly 50 M without associated toxicity
272
[36] [66] [67]. One possible explanation for this difference is that in vitro studies do not entirely 273 represent all the biological interactions that take place in the human body. In addition, it is possible 274 that at this high concentration, atovaquone is not antiviral and thus would need to be optimized at 275 lower concentrations for its antiviral function in humans.
276
To address the stage in the viral life cycle where atovaquone acts, we performed viral 277 entry assays by infecting cells in the presence or absence of atovaquone and then adding media 278 with or without the compound after infection. Here, we found that adding atovaquone at the time 279 of infection had no effect on virion production whereas adding atovaquone after infection was able 280 to reduce ZIKV replication, indicating that atovaquone is acting post entry. We then performed 281 time-of-addition assays where we added atovaquone one hour before, during, and at multiple time 282 points post infection. We found that only early during infection, within the first two to four hours 283 post infection, was atovaquone able to inhibit viral replication. These data are similar to what has 284 been seen for the antiviral effects of brequinar on DENV [20], [41], suggesting atovaquone may 285 function by a similar mechanism. Given these results, we hypothesized that atovaquone is 286 functioning during the initial steps of ZIKV RNA replication and blocking virion production through 287 the inhibition of RNA replication. When we quantified ZIKV RNA levels over time we found that 288 indeed atovaquone treatment significantly reduced viral RNA synthesis.
289
Atovaquone is thought to function primarily through the inhibition of mitochondrial 290 cytochrome complex III and thus inhibition of mitochondrial function in the parasite [34] , [36] , [37] .
291
Using an MTT assay of cell proliferation measured through mitochondrial function we also saw 13 292 that atovaquone was able to reduce mitochondrial function in all cell lines we analyzed, yet these 293 cells were shown to be viable by Sytox Green staining. Atovaquone also functions through 294 inhibiting dihydroorotate dehydrogenase (DHODH) [33] , an enzyme involved in pyrimidine 295 biosynthesis and in particular the synthesis of uridine monophosphate (UMP). Given the striking 296 similarities to brequinar, another pyrimidine biosynthesis inhibitor, and that atovaquone 297 specifically inhibited ZIKV RNA synthesis we hypothesized that this inhibition was through 298 intracellular nucleotide depletion. To address this, we added exogenous nucleosides in the 299 presence of atovaquone and indeed found that the addition of uridine was able to rescue ZIKV 300 infection in all cell types, although to various extents. Moreover, we found that the addition of 301 uridine was able to specifically rescue ZIKV RNA synthesis indicating that the antiviral effects of 302 the drugs are through the depletion of intracellular nucleotides. We found it interesting that human
303
293T and JEG3 cells were unable to be completely rescued with the addition of uridine. However,
304
it has been shown that nucleotide depletion will induce an antiviral innate immune response [26],
305
[27], [40] , and we hypothesize that a similar mechanism may be induced in these cells allowing 306 them to retain antiviral function in the presence of exogenous uridine. One striking finding was 307 that atovaquone in the presence of cytidine had an additive antiviral effect in several cell lines 308 suggesting again that multiple cellular pathways may be at play. 
378
Working virus stocks were generated by passaging virus over BHK-21 cells and viral titers were 379 quantified by plaque assay as described above. 400 in a volume of 5 μl that was pre-incubated with 15 μM, 5 μM, or 1.6 μM atovaquone for 1 hour.
401
Atovaquone was maintained in the culture media at the same concentrations throughout 6 days 402 of culture. Supernatants were collected and media changed every other day. 
403

454
GAAGGTCGGAGTCAACGGATTT -3' and 5'-GAATTTGCCATGGGTGGAAT -3') and ZIKV (5'-
455
AGATGACTGCGTTGTGAAGC-3' and 5'-GAGCAGAACGGGACTTCTTC-3').
456
Virus entry and time-of-addition assays. To assay for the role of atovaquone in viral entry,
457
293T cells were infected with ZIKV at an MOI of 0. 
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Unabsorbed virus was washed off and media was added containing DMSO or 4.5 M atovaquone.
733
Infectious virus was quantified 24 hours post infection by plaque assay. The mean and SEM are 734 shown, n=3, Students t-test. *** p<0.005.
